Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$848M |
| 2 |
Tesla
TSLA
|
+$759M |
| 3 |
Home Depot
HD
|
+$653M |
| 4 |
Meta Platforms (Facebook)
META
|
+$567M |
| 5 |
Wells Fargo
WFC
|
+$421M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$786M |
| 2 |
Berkshire Hathaway Class A
BRK.A
|
+$409M |
| 3 |
Micron Technology
MU
|
+$379M |
| 4 |
AT&T
T
|
+$372M |
| 5 |
Medtronic
MDT
|
+$370M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.69% |
| 2 | Technology | 14.95% |
| 3 | Consumer Discretionary | 11.34% |
| 4 | Consumer Staples | 10.7% |
| 5 | Communication Services | 8.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
iShares Broad USD Investment Grade Corporate Bond ETF
USIG
$17.3B
| $1.08M | ﹤0.01% |
+19,700
| New | +$1.12M |
|
2677
IQ ARB Merger Arbitrage ETF
MNA
$252M
| $1.08M | ﹤0.01% |
33,905
+25,105
| +285% | +$799K |
|
|
YMAB
2678
DELISTED
Y-mAbs Therapeutics
YMAB
| $1.08M | ﹤0.01% |
91,000
-7,600
| -8% | -$78K |
|
2679
Jaguar Health
JAGX
$4.91M
| – | – |
0
| – | – |
|
2680
Momentus
MNTS
$78.9M
| $1.08M | ﹤0.01% |
27
+10
| +59% | +$385K |
|
2681
Envela
ELA
$565M
| $1.08M | ﹤0.01% |
231,184
-44,806
| -16% | -$186K |
|
2682
Alta Equipment Group
ALTG
$226M
| $1.07M | ﹤0.01% |
86,600
+14,000
| +19% | +$184K |
|
2683
Comstock Holding Companies
CHCI
$150M
| $1.07M | ﹤0.01% |
179,364
-3,800
| -2% | -$18.5K |
|
2684
Nurix Therapeutics
NRIX
$2.38B
| $1.07M | ﹤0.01% |
+76,200
| New | +$1.35M |
|
|
AMPE
2685
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| $1.07M | ﹤0.01% |
7,559
-449
| -6% | -$65.6K |
|
2686
Invesco S&P Global Water Index ETF
CGW
$1.06B
| $1.06M | ﹤0.01% |
20,300
+4,971
| +32% | +$264K |
|
2687
Axogen
AXGN
$2.46B
| $1.06M | ﹤0.01% |
+133,900
| New | +$1.16M |
|
|
SCPH
2688
DELISTED
scPharmaceuticals
SCPH
| $1.06M | ﹤0.01% |
186,086
-2,900
| -2% | -$14.2K |
|
|
BWIN
2689
Baldwin Insurance Group
BWIN
$2.82B
| $1.06M | ﹤0.01% |
+39,400
| New | +$1.14M |
|
|
BNR
2690
Burning Rock Biotech
BNR
$95M
| $1.05M | ﹤0.01% |
11,360
-5,179
| -31% | -$450K |
|
2691
GCM Grosvenor
GCMG
$798M
| $1.05M | ﹤0.01% |
108,600
-143,181
| -57% | -$1.42M |
|
2692
Olema Pharmaceuticals
OLMA
$983M
| $1.05M | ﹤0.01% |
+247,332
| New | +$1.36M |
|
2693
Invesco S&P 500 Quality ETF
SPHQ
$19.5B
| $1.05M | ﹤0.01% |
21,100
-6,100
| -22% | -$307K |
|
2694
AerSale
ASLE
$306M
| $1.05M | ﹤0.01% |
66,900
-4,300
| -6% | -$66.1K |
|
|
HARP
2695
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $1.05M | ﹤0.01% |
21,120
+15,960
| +309% | +$827K |
|
2696
Bank of Hawaii
BOH
$3.18B
| $1.05M | ﹤0.01% |
12,500
-20,800
| -62% | -$1.8M |
|
2697
Ameris Bancorp
ABCB
$5.94B
| $1.05M | ﹤0.01% |
+23,869
| New | +$1.18M |
|
2698
FVCBankcorp
FVCB
$339M
| $1.05M | ﹤0.01% |
63,099
-1,026
| -2% | -$17K |
|
2699
4D Molecular Therapeutics
FDMT
$521M
| $1.04M | ﹤0.01% |
69,100
+24,300
| +54% | +$382K |
|
|
GRTX
2700
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $1.04M | ﹤0.01% |
+439,134
| New | +$1.14M |
|
Similar funds
Renaissance Technologies's Q1 2022 Portfolio in Review
As of Q1 2022, Renaissance Technologies held 4,686 positions worth $85.2B, up 6% from $80.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies deployed $8.98B of net new capital in Q1 2022, opening 822 new positions and adding to 1,556 existing holdings. Its largest new stake was Advanced Micro Devices: 7,107,290 shares worth $777M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Berkshire Hathaway Class A, an estimated $409M trimmed.
- Renaissance Technologies's largest Q1 2022 buy was Advanced Micro Devices: 7,107,290 shares worth $777M.
- Renaissance Technologies added most to Tesla in Q1 2022, an estimated $759M increase.
- Renaissance Technologies's biggest Q1 2022 reduction was Berkshire Hathaway Class A, cutting an estimated $409M.
- Renaissance Technologies fully exited Microsoft in Q1 2022, selling an estimated $786M.
- Renaissance Technologies's ten largest holdings make up 12% of its $85.2B portfolio in Q1 2022.
- Renaissance Technologies opened 822 new positions and closed 650 in Q1 2022.
- Renaissance Technologies's portfolio value rose 6% quarter-over-quarter to $85.2B.
Based on Renaissance Technologies's 13F filing for Q1 2022, filed 13 May 2022.